麻豆传媒

Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity

But no overall survival benefit seen in confirmatory trial

Benefit seen in all prespecified subgroups, including high-risk patients

Better disease outcomes, measures of cognition, and quality-of-life vs standard care, study finds

New standard of care for patients in first remission?

Increased factor VIII levels to mild or moderate range, with annualized bleeding rate of zero

Treatment tied to fewer vaso-occlusive pain events, hospitalizations versus placebo

AMPLIFY trial paves the way for FDA approval of acalabrutinib plus venetoclax

Daratumumab significantly improved PFS, OS, but identity of high-risk population remains elusive

Complete responses seen in 43% of patients in expansion cohort of EPCORE CLL-1 study

Rilzabrutinib specifically designed to reduce platelet-targeting autoantibodies

Two-thirds of phase II patients had a complete response at 12 weeks of treatment

High-fiber diets tied to improved outcomes in stem-cell transplants, slowing myeloma precursors

20% lower risk of VTE observed in large retrospective study of diabetes patients